

# Cancer Generics Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/C8DDC1767A68EN.html>

Date: March 2022

Pages: 112

Price: US\$ 3,250.00 (Single User License)

ID: C8DDC1767A68EN

## Abstracts

This report contains market size and forecasts of Cancer Generics in Global, including the following market information:

Global Cancer Generics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Cancer Generics market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Chemotherapy Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Cancer Generics include Teva Pharmaceuticals, Pfizer, Accord Healthcare, Amneal Pharmaceuticals, Mylan, DrReddy Laboratories, Bedford Pharma, Hikma and Cipla, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cancer Generics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Cancer Generics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Cancer Generics Market Segment Percentages, by Type, 2021 (%)

Chemotherapy

Biological Targeted Therapy Drugs

Prescription Drugs

Chinese Patent Medicine

Other

Global Cancer Generics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Cancer Generics Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Drug Center

Other

Global Cancer Generics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Cancer Generics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Cancer Generics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Cancer Generics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Teva Pharmaceuticals

Pfizer

Accord Healthcare

Amneal Pharmaceuticals

Mylan

DrReddy Laboratories

Bedford Pharma

Hikma

Cipla

Shilpa Medicare

Fresenius Kabi

Zydus Pharmaceuticals

Neopharm

Netco

Mayne Pharma

Alvogen

Glenmark

HBT Labs

Gland

Qilu Pharmaceuticals

Akorn Pharmaceuticals

MSN Group

Wockhardt

Rising Pharma

Apotex

Taro Pharmaceuticals

Sun Pharma

Alkem Laboratories

Endo Pharma

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Cancer Generics Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Cancer Generics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL CANCER GENERICS OVERALL MARKET SIZE**

- 2.1 Global Cancer Generics Market Size: 2021 VS 2028
- 2.2 Global Cancer Generics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Cancer Generics Players in Global Market
- 3.2 Top Global Cancer Generics Companies Ranked by Revenue
- 3.3 Global Cancer Generics Revenue by Companies
- 3.4 Top 3 and Top 5 Cancer Generics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Cancer Generics Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Cancer Generics Players in Global Market
  - 3.6.1 List of Global Tier 1 Cancer Generics Companies
  - 3.6.2 List of Global Tier 2 and Tier 3 Cancer Generics Companies

### **4 MARKET SIGHTS BY PRODUCT**

#### 4.1 Overview

4.1.1 by Type - Global Cancer Generics Market Size Markets, 2021 & 2028

4.1.2 Chemotherapy

4.1.3 Biological Targeted Therapy Drugs

4.1.4 Prescription Drugs

4.1.5 Chinese Patent Medicine

4.1.6 Other

#### 4.2 By Type - Global Cancer Generics Revenue & Forecasts

4.2.1 By Type - Global Cancer Generics Revenue, 2017-2022

4.2.2 By Type - Global Cancer Generics Revenue, 2023-2028

4.2.3 By Type - Global Cancer Generics Revenue Market Share, 2017-2028

### 5 SIGHTS BY APPLICATION

#### 5.1 Overview

5.1.1 By Application - Global Cancer Generics Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Drug Center

5.1.5 Other

#### 5.2 By Application - Global Cancer Generics Revenue & Forecasts

5.2.1 By Application - Global Cancer Generics Revenue, 2017-2022

5.2.2 By Application - Global Cancer Generics Revenue, 2023-2028

5.2.3 By Application - Global Cancer Generics Revenue Market Share, 2017-2028

### 6 SIGHTS BY REGION

#### 6.1 By Region - Global Cancer Generics Market Size, 2021 & 2028

#### 6.2 By Region - Global Cancer Generics Revenue & Forecasts

6.2.1 By Region - Global Cancer Generics Revenue, 2017-2022

6.2.2 By Region - Global Cancer Generics Revenue, 2023-2028

6.2.3 By Region - Global Cancer Generics Revenue Market Share, 2017-2028

#### 6.3 North America

6.3.1 By Country - North America Cancer Generics Revenue, 2017-2028

6.3.2 US Cancer Generics Market Size, 2017-2028

6.3.3 Canada Cancer Generics Market Size, 2017-2028

6.3.4 Mexico Cancer Generics Market Size, 2017-2028

#### 6.4 Europe

6.4.1 By Country - Europe Cancer Generics Revenue, 2017-2028



- 6.4.2 Germany Cancer Generics Market Size, 2017-2028
- 6.4.3 France Cancer Generics Market Size, 2017-2028
- 6.4.4 U.K. Cancer Generics Market Size, 2017-2028
- 6.4.5 Italy Cancer Generics Market Size, 2017-2028
- 6.4.6 Russia Cancer Generics Market Size, 2017-2028
- 6.4.7 Nordic Countries Cancer Generics Market Size, 2017-2028
- 6.4.8 Benelux Cancer Generics Market Size, 2017-2028

## 6.5 Asia

- 6.5.1 By Region - Asia Cancer Generics Revenue, 2017-2028
- 6.5.2 China Cancer Generics Market Size, 2017-2028
- 6.5.3 Japan Cancer Generics Market Size, 2017-2028
- 6.5.4 South Korea Cancer Generics Market Size, 2017-2028
- 6.5.5 Southeast Asia Cancer Generics Market Size, 2017-2028
- 6.5.6 India Cancer Generics Market Size, 2017-2028

## 6.6 South America

- 6.6.1 By Country - South America Cancer Generics Revenue, 2017-2028
- 6.6.2 Brazil Cancer Generics Market Size, 2017-2028
- 6.6.3 Argentina Cancer Generics Market Size, 2017-2028

## 6.7 Middle East & Africa

- 6.7.1 By Country - Middle East & Africa Cancer Generics Revenue, 2017-2028
- 6.7.2 Turkey Cancer Generics Market Size, 2017-2028
- 6.7.3 Israel Cancer Generics Market Size, 2017-2028
- 6.7.4 Saudi Arabia Cancer Generics Market Size, 2017-2028
- 6.7.5 UAE Cancer Generics Market Size, 2017-2028

## 7 PLAYERS PROFILES

### 7.1 Teva Pharmaceuticals

- 7.1.1 Teva Pharmaceuticals Corporate Summary
- 7.1.2 Teva Pharmaceuticals Business Overview
- 7.1.3 Teva Pharmaceuticals Cancer Generics Major Product Offerings
- 7.1.4 Teva Pharmaceuticals Cancer Generics Revenue in Global Market (2017-2022)
- 7.1.5 Teva Pharmaceuticals Key News

### 7.2 Pfizer

- 7.2.1 Pfizer Corporate Summary
- 7.2.2 Pfizer Business Overview
- 7.2.3 Pfizer Cancer Generics Major Product Offerings
- 7.2.4 Pfizer Cancer Generics Revenue in Global Market (2017-2022)
- 7.2.5 Pfizer Key News

### 7.3 Accord Healthcare

7.3.1 Accord Healthcare Corporate Summary

7.3.2 Accord Healthcare Business Overview

7.3.3 Accord Healthcare Cancer Generics Major Product Offerings

7.3.4 Accord Healthcare Cancer Generics Revenue in Global Market (2017-2022)

7.3.5 Accord Healthcare Key News

### 7.4 Amneal Pharmaceuticals

7.4.1 Amneal Pharmaceuticals Corporate Summary

7.4.2 Amneal Pharmaceuticals Business Overview

7.4.3 Amneal Pharmaceuticals Cancer Generics Major Product Offerings

7.4.4 Amneal Pharmaceuticals Cancer Generics Revenue in Global Market (2017-2022)

7.4.5 Amneal Pharmaceuticals Key News

### 7.5 Mylan

7.5.1 Mylan Corporate Summary

7.5.2 Mylan Business Overview

7.5.3 Mylan Cancer Generics Major Product Offerings

7.5.4 Mylan Cancer Generics Revenue in Global Market (2017-2022)

7.5.5 Mylan Key News

### 7.6 DrReddy Laboratories

7.6.1 DrReddy Laboratories Corporate Summary

7.6.2 DrReddy Laboratories Business Overview

7.6.3 DrReddy Laboratories Cancer Generics Major Product Offerings

7.6.4 DrReddy Laboratories Cancer Generics Revenue in Global Market (2017-2022)

7.6.5 DrReddy Laboratories Key News

### 7.7 Bedford Pharma

7.7.1 Bedford Pharma Corporate Summary

7.7.2 Bedford Pharma Business Overview

7.7.3 Bedford Pharma Cancer Generics Major Product Offerings

7.7.4 Bedford Pharma Cancer Generics Revenue in Global Market (2017-2022)

7.7.5 Bedford Pharma Key News

### 7.8 Hikma

7.8.1 Hikma Corporate Summary

7.8.2 Hikma Business Overview

7.8.3 Hikma Cancer Generics Major Product Offerings

7.8.4 Hikma Cancer Generics Revenue in Global Market (2017-2022)

7.8.5 Hikma Key News

### 7.9 Cipla

7.9.1 Cipla Corporate Summary

- 7.9.2 Cipla Business Overview
- 7.9.3 Cipla Cancer Generics Major Product Offerings
- 7.9.4 Cipla Cancer Generics Revenue in Global Market (2017-2022)
- 7.9.5 Cipla Key News
- 7.10 Shilpa Medicare
  - 7.10.1 Shilpa Medicare Corporate Summary
  - 7.10.2 Shilpa Medicare Business Overview
  - 7.10.3 Shilpa Medicare Cancer Generics Major Product Offerings
  - 7.10.4 Shilpa Medicare Cancer Generics Revenue in Global Market (2017-2022)
  - 7.10.5 Shilpa Medicare Key News
- 7.11 Fresenius Kabi
  - 7.11.1 Fresenius Kabi Corporate Summary
  - 7.11.2 Fresenius Kabi Business Overview
  - 7.11.3 Fresenius Kabi Cancer Generics Major Product Offerings
  - 7.11.4 Fresenius Kabi Cancer Generics Revenue in Global Market (2017-2022)
  - 7.11.5 Fresenius Kabi Key News
- 7.12 Zydus Pharmaceuticals
  - 7.12.1 Zydus Pharmaceuticals Corporate Summary
  - 7.12.2 Zydus Pharmaceuticals Business Overview
  - 7.12.3 Zydus Pharmaceuticals Cancer Generics Major Product Offerings
  - 7.12.4 Zydus Pharmaceuticals Cancer Generics Revenue in Global Market (2017-2022)
  - 7.12.5 Zydus Pharmaceuticals Key News
- 7.13 Neopharm
  - 7.13.1 Neopharm Corporate Summary
  - 7.13.2 Neopharm Business Overview
  - 7.13.3 Neopharm Cancer Generics Major Product Offerings
  - 7.13.4 Neopharm Cancer Generics Revenue in Global Market (2017-2022)
  - 7.13.5 Neopharm Key News
- 7.14 Netco
  - 7.14.1 Netco Corporate Summary
  - 7.14.2 Netco Business Overview
  - 7.14.3 Netco Cancer Generics Major Product Offerings
  - 7.14.4 Netco Cancer Generics Revenue in Global Market (2017-2022)
  - 7.14.5 Netco Key News
- 7.15 Mayne Pharma
  - 7.15.1 Mayne Pharma Corporate Summary
  - 7.15.2 Mayne Pharma Business Overview
  - 7.15.3 Mayne Pharma Cancer Generics Major Product Offerings

- 7.15.4 Mayne Pharma Cancer Generics Revenue in Global Market (2017-2022)
- 7.15.5 Mayne Pharma Key News
- 7.16 Alvogen
  - 7.16.1 Alvogen Corporate Summary
  - 7.16.2 Alvogen Business Overview
  - 7.16.3 Alvogen Cancer Generics Major Product Offerings
  - 7.16.4 Alvogen Cancer Generics Revenue in Global Market (2017-2022)
  - 7.16.5 Alvogen Key News
- 7.17 Glenmark
  - 7.17.1 Glenmark Corporate Summary
  - 7.17.2 Glenmark Business Overview
  - 7.17.3 Glenmark Cancer Generics Major Product Offerings
  - 7.17.4 Glenmark Cancer Generics Revenue in Global Market (2017-2022)
  - 7.17.5 Glenmark Key News
- 7.18 HBT Labs
  - 7.18.1 HBT Labs Corporate Summary
  - 7.18.2 HBT Labs Business Overview
  - 7.18.3 HBT Labs Cancer Generics Major Product Offerings
  - 7.18.4 HBT Labs Cancer Generics Revenue in Global Market (2017-2022)
  - 7.18.5 HBT Labs Key News
- 7.19 Gland
  - 7.19.1 Gland Corporate Summary
  - 7.19.2 Gland Business Overview
  - 7.19.3 Gland Cancer Generics Major Product Offerings
  - 7.19.4 Gland Cancer Generics Revenue in Global Market (2017-2022)
  - 7.19.5 Gland Key News
- 7.20 Qilu Pharmaceuticals
  - 7.20.1 Qilu Pharmaceuticals Corporate Summary
  - 7.20.2 Qilu Pharmaceuticals Business Overview
  - 7.20.3 Qilu Pharmaceuticals Cancer Generics Major Product Offerings
  - 7.20.4 Qilu Pharmaceuticals Cancer Generics Revenue in Global Market (2017-2022)
  - 7.20.5 Qilu Pharmaceuticals Key News
- 7.21 Akorn Pharmaceuticals
  - 7.21.1 Akorn Pharmaceuticals Corporate Summary
  - 7.21.2 Akorn Pharmaceuticals Business Overview
  - 7.21.3 Akorn Pharmaceuticals Cancer Generics Major Product Offerings
  - 7.21.4 Akorn Pharmaceuticals Cancer Generics Revenue in Global Market (2017-2022)
  - 7.21.5 Akorn Pharmaceuticals Key News

## 7.22 MSN Group

- 7.22.1 MSN Group Corporate Summary
- 7.22.2 MSN Group Business Overview
- 7.22.3 MSN Group Cancer Generics Major Product Offerings
- 7.22.4 MSN Group Cancer Generics Revenue in Global Market (2017-2022)
- 7.22.5 MSN Group Key News

## 7.23 Wockhardt

- 7.23.1 Wockhardt Corporate Summary
- 7.23.2 Wockhardt Business Overview
- 7.23.3 Wockhardt Cancer Generics Major Product Offerings
- 7.23.4 Wockhardt Cancer Generics Revenue in Global Market (2017-2022)
- 7.23.5 Wockhardt Key News

## 7.24 Rising Pharma

- 7.24.1 Rising Pharma Corporate Summary
- 7.24.2 Rising Pharma Business Overview
- 7.24.3 Rising Pharma Cancer Generics Major Product Offerings
- 7.24.4 Rising Pharma Cancer Generics Revenue in Global Market (2017-2022)
- 7.24.5 Rising Pharma Key News

## 7.25 Apotex

- 7.25.1 Apotex Corporate Summary
- 7.25.2 Apotex Business Overview
- 7.25.3 Apotex Cancer Generics Major Product Offerings
- 7.25.4 Apotex Cancer Generics Revenue in Global Market (2017-2022)
- 7.25.5 Apotex Key News

## 7.26 Taro Pharmaceuticals

- 7.26.1 Taro Pharmaceuticals Corporate Summary
- 7.26.2 Taro Pharmaceuticals Business Overview
- 7.26.3 Taro Pharmaceuticals Cancer Generics Major Product Offerings
- 7.26.4 Taro Pharmaceuticals Cancer Generics Revenue in Global Market (2017-2022)
- 7.26.5 Taro Pharmaceuticals Key News

## 7.27 Sun Pharma

- 7.27.1 Sun Pharma Corporate Summary
- 7.27.2 Sun Pharma Business Overview
- 7.27.3 Sun Pharma Cancer Generics Major Product Offerings
- 7.27.4 Sun Pharma Cancer Generics Revenue in Global Market (2017-2022)
- 7.27.5 Sun Pharma Key News

## 7.28 Alkem Laboratories

- 7.28.1 Alkem Laboratories Corporate Summary
- 7.28.2 Alkem Laboratories Business Overview

7.28.3 Alkem Laboratories Cancer Generics Major Product Offerings

7.28.4 Alkem Laboratories Cancer Generics Revenue in Global Market (2017-2022)

7.28.5 Alkem Laboratories Key News

7.29 Endo Pharma

7.29.1 Endo Pharma Corporate Summary

7.29.2 Endo Pharma Business Overview

7.29.3 Endo Pharma Cancer Generics Major Product Offerings

7.29.4 Endo Pharma Cancer Generics Revenue in Global Market (2017-2022)

7.29.5 Endo Pharma Key News

## **8 CONCLUSION**

## **9 APPENDIX**

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer



## List Of Tables

### LIST OF TABLES

- Table 1. Cancer Generics Market Opportunities & Trends in Global Market
- Table 2. Cancer Generics Market Drivers in Global Market
- Table 3. Cancer Generics Market Restraints in Global Market
- Table 4. Key Players of Cancer Generics in Global Market
- Table 5. Top Cancer Generics Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Cancer Generics Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Cancer Generics Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Cancer Generics Product Type
- Table 9. List of Global Tier 1 Cancer Generics Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Cancer Generics Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Cancer Generics Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Cancer Generics Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - Cancer Generics Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global Cancer Generics Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - Cancer Generics Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - Cancer Generics Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global Cancer Generics Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global Cancer Generics Revenue (US\$, Mn), 2017-2022
- Table 19. By Region - Global Cancer Generics Revenue (US\$, Mn), 2023-2028
- Table 20. By Country - North America Cancer Generics Revenue, (US\$, Mn), 2017-2022
- Table 21. By Country - North America Cancer Generics Revenue, (US\$, Mn), 2023-2028
- Table 22. By Country - Europe Cancer Generics Revenue, (US\$, Mn), 2017-2022
- Table 23. By Country - Europe Cancer Generics Revenue, (US\$, Mn), 2023-2028
- Table 24. By Region - Asia Cancer Generics Revenue, (US\$, Mn), 2017-2022
- Table 25. By Region - Asia Cancer Generics Revenue, (US\$, Mn), 2023-2028
- Table 26. By Country - South America Cancer Generics Revenue, (US\$, Mn), 2017-2022
- Table 27. By Country - South America Cancer Generics Revenue, (US\$, Mn), 2023-2028
- Table 28. By Country - Middle East & Africa Cancer Generics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Cancer Generics Revenue, (US\$, Mn), 2023-2028

Table 30. Teva Pharmaceuticals Corporate Summary

Table 31. Teva Pharmaceuticals Cancer Generics Product Offerings

Table 32. Teva Pharmaceuticals Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 33. Pfizer Corporate Summary

Table 34. Pfizer Cancer Generics Product Offerings

Table 35. Pfizer Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 36. Accord Healthcare Corporate Summary

Table 37. Accord Healthcare Cancer Generics Product Offerings

Table 38. Accord Healthcare Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 39. Amneal Pharmaceuticals Corporate Summary

Table 40. Amneal Pharmaceuticals Cancer Generics Product Offerings

Table 41. Amneal Pharmaceuticals Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 42. Mylan Corporate Summary

Table 43. Mylan Cancer Generics Product Offerings

Table 44. Mylan Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 45. DrReddy Laboratories Corporate Summary

Table 46. DrReddy Laboratories Cancer Generics Product Offerings

Table 47. DrReddy Laboratories Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 48. Bedford Pharma Corporate Summary

Table 49. Bedford Pharma Cancer Generics Product Offerings

Table 50. Bedford Pharma Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 51. Hikma Corporate Summary

Table 52. Hikma Cancer Generics Product Offerings

Table 53. Hikma Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 54. Cipla Corporate Summary

Table 55. Cipla Cancer Generics Product Offerings

Table 56. Cipla Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 57. Shilpa Medicare Corporate Summary

Table 58. Shilpa Medicare Cancer Generics Product Offerings

Table 59. Shilpa Medicare Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 60. Fresenius Kabi Corporate Summary

Table 61. Fresenius Kabi Cancer Generics Product Offerings

Table 62. Fresenius Kabi Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 63. Zydus Pharmaceuticals Corporate Summary

Table 64. Zydus Pharmaceuticals Cancer Generics Product Offerings

Table 65. Zydus Pharmaceuticals Cancer Generics Revenue (US\$, Mn), (2017-2022)

Table 66. Neopharm Corporate Summary



- Table 67. Neopharm Cancer Generics Product Offerings
- Table 68. Neopharm Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 69. Netco Corporate Summary
- Table 70. Netco Cancer Generics Product Offerings
- Table 71. Netco Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 72. Mayne Pharma Corporate Summary
- Table 73. Mayne Pharma Cancer Generics Product Offerings
- Table 74. Mayne Pharma Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 75. Alvogen Corporate Summary
- Table 76. Alvogen Cancer Generics Product Offerings
- Table 77. Alvogen Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 78. Glenmark Corporate Summary
- Table 79. Glenmark Cancer Generics Product Offerings
- Table 80. Glenmark Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 81. HBT Labs Corporate Summary
- Table 82. HBT Labs Cancer Generics Product Offerings
- Table 83. HBT Labs Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 84. Gland Corporate Summary
- Table 85. Gland Cancer Generics Product Offerings
- Table 86. Gland Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 87. Qilu Pharmaceuticals Corporate Summary
- Table 88. Qilu Pharmaceuticals Cancer Generics Product Offerings
- Table 89. Qilu Pharmaceuticals Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 90. Akorn Pharmaceuticals Corporate Summary
- Table 91. Akorn Pharmaceuticals Cancer Generics Product Offerings
- Table 92. Akorn Pharmaceuticals Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 93. MSN Group Corporate Summary
- Table 94. MSN Group Cancer Generics Product Offerings
- Table 95. MSN Group Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 96. Wockhardt Corporate Summary
- Table 97. Wockhardt Cancer Generics Product Offerings
- Table 98. Wockhardt Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 99. Rising Pharma Corporate Summary
- Table 100. Rising Pharma Cancer Generics Product Offerings
- Table 101. Rising Pharma Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 102. Apotex Corporate Summary
- Table 103. Apotex Cancer Generics Product Offerings
- Table 104. Apotex Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 105. Taro Pharmaceuticals Corporate Summary

- Table 106. Taro Pharmaceuticals Cancer Generics Product Offerings
- Table 107. Taro Pharmaceuticals Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 108. Sun Pharma Corporate Summary
- Table 109. Sun Pharma Cancer Generics Product Offerings
- Table 110. Sun Pharma Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 111. Alkem Laboratories Corporate Summary
- Table 112. Alkem Laboratories Cancer Generics Product Offerings
- Table 113. Alkem Laboratories Cancer Generics Revenue (US\$, Mn), (2017-2022)
- Table 114. Endo Pharma Corporate Summary
- Table 115. Endo Pharma Cancer Generics Product Offerings
- Table 116. Endo Pharma Cancer Generics Revenue (US\$, Mn), (2017-2022)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Cancer Generics Segment by Type in 2021
- Figure 2. Cancer Generics Segment by Application in 2021
- Figure 3. Global Cancer Generics Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Cancer Generics Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Cancer Generics Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Cancer Generics Revenue in 2021
- Figure 8. By Type - Global Cancer Generics Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Cancer Generics Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Cancer Generics Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Cancer Generics Revenue Market Share, 2017-2028
- Figure 12. US Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Cancer Generics Revenue Market Share, 2017-2028
- Figure 16. Germany Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Cancer Generics Revenue Market Share, 2017-2028
- Figure 24. China Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 28. India Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country - South America Cancer Generics Revenue Market Share, 2017-2028
- Figure 30. Brazil Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 31. Argentina Cancer Generics Revenue, (US\$, Mn), 2017-2028
- Figure 32. By Country - Middle East & Africa Cancer Generics Revenue Market Share, 2017-2028

Figure 33. Turkey Cancer Generics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Cancer Generics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Cancer Generics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Cancer Generics Revenue, (US\$, Mn), 2017-2028

Figure 37. Teva Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Pfizer Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Accord Healthcare Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Amneal Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Mylan Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. DrReddy Laboratories Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Bedford Pharma Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Hikma Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Cipla Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Shilpa Medicare Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Fresenius Kabi Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Zydus Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Neopharm Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Netco Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. Mayne Pharma Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 52. Alvogen Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 53. Glenmark Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. HBT Labs Cancer Generics Revenue Year Over Year Growth (US\$, Mn) &

(2017-2022)

Figure 55. Gland Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 56. Qilu Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 57. Akorn Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 58. MSN Group Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 59. Wockhardt Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 60. Rising Pharma Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 61. Apotex Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 62. Taro Pharmaceuticals Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 63. Sun Pharma Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 64. Alkem Laboratories Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 65. Endo Pharma Cancer Generics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Cancer Generics Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/C8DDC1767A68EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8DDC1767A68EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970